General MedicationsINTRAVENOUSStandard
TERLIVAZ
TERLIPRESSIN ACETATE
Standard Dose
EQ 0.85MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview TERLIVAZ is listed in Drugs@FDA under application 022231 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TERLIPRESSIN ACETATE Form and strength POWDER;INTRAVENOUS - EQ 0.85MG BASE/VIAL Sponsor MALLINCKRODT IRELAND Submission history Latest submission status date: 2023-01-09 00:00:00.
Structured Monograph
Clinical summary
Approval overview TERLIVAZ is listed in Drugs@FDA under application 022231 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TERLIPRESSIN ACETATE Form and strength POWDER;INTRAVENOUS - EQ 0.85MG BASE/VIAL Sponsor MALLINCKRODT IRELAND Submission history Latest submission status date: 2023-01-09 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.